REATA

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

Reata is the leader in developing novel oral anti-inflammatory drugs targeting Nrf2. This important biological target has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress, and Reata’s drugs are its most potent known inducers.

- LEARN MORE

	6.6.2009 - Reata Presents Promising Data on Bardoxolone at American Diabetes Association Annual Scientific Meeting; Phase II Results Demonstrate Significant Increase in Glomerular Filtration Rate in Diabetic Patients with Advanced Chronic Kidney Disease
	Reata Pharmaceuticals, Inc. today announced that results of a Phase II clinical trial of bardoxolone, its lead antioxidant inflammation modulator (AIM), conducted in 60 diabetic patients with advanced chronic kidney disease (CKD) will be the subject of two oral presentations at the 69th annual meeting of the American Diabetes Association. The final data from the study demonstrated that patients treated with bardoxolone experienced a greater than 20 percent increase (p<0.0001) over baseline in their estimated glomerular filtration rate (GFR), a measure of the kidney's filtration capacity and the primary endpoint of the study. CKD is a progressive and incurable disease, and currently approved treatments only modestly reduce the rate of decline in the kidney's GFR over time. In the bardoxolone CKD study, approximately 90 percent of patients on drug experienced an increase in their GFR, and patients with more severe stage 4 CKD at baseline experienced an even greater (36 percent) increase in GFR (p<0.0001). Based on the results of this Phase II clinical trial, Reata has initiated a longer term, late stage trial of bardoxolone in patients with diabetes and advanced CKD.
	3.25.2009 - Reata Completes Financing and Expands Team to Capture Opportunity Created by Encouraging Clinical Data in Chronic Kidney Disease; Late Stage Trial Initiated in Patients with Advanced CKD
	IRVING, TX - March 25, 2009 -- Reata Pharmaceuticals, Inc. announced today that the company has made significant progress in advancing its lead project, bardoxolone methyl, for the treatment of chronic kidney disease (CKD). Based on encouraging results from a recently completed Phase 2a trial, the company has initiated a Phase 2b trial of this agent in patients with advanced chronic kidney disease (CKD) and Type 2 diabetes. To finance this trial, the company closed $32.0 million in the first tranche of a private financing round. Additionally, the company recently added Eric Grossman, a Nephrologist with significant drug development experience, to its team as the Vice President of Clinical Development and Medical Affairs.
	2.18.2009 - Reata's AIM Shows Promise for COPD in Study Published in Proceedings of the National Academy of Sciences
	Reata Pharmaceuticals, Inc. announced today that its Antioxidant Inflammation Modulator (AIM) CDDO-Im (also known as RTA 403) conferred protection to mice during chronic exposure to cigarette smoke, protecting against damage and related symptoms that cause chronic obstructive pulmonary disease (COPD) in a study published in the Proceedings of the National Academy of Sciences (January 6, 2009 issue) and featured in a �Research Highlights� review in Nature Reviews Drug Discovery (January 23, 2009 issue). The study was conducted by researchers at Johns Hopkins University, and Reata provided the AIM used in the study.
	10.28.2008 - Reata to Present at BIO Investor Forum
	Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, October 30, 2008 at the 7th Annual BIO Investor Forum at 11:30 a.m., Pacific Time. The event is being held at the Pacific Hotel in San Francisco, California.
	10.15.2008 - FDA Grants Orphan Drug Status to Reata's RTA 402 for Treatment of Pancreatic Cancer
	Reata Pharmaceuticals, Inc. announces that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

	+ ARCHIVED NEWS

Reata is developing a portfolio of Antioxidant Inflammation Modulators (AIMs) that target Nrf2. AIMs represent a breakthrough in the regulation of inflammation and oxidative stress with a number of advantages over other approaches:

	AIMs mimic the body’s natural mechanism for resolving inflammation
	AIMs regulate many inflammatory mediators simultaneously
	Broad applications in various diseases: renal/cardiovascular, autoimmune, CNS, pulmonary diseases, and cancer
	Simple, once-daily, oral administration

The most advanced AIM in Reata's portfolio, bardoxolone methyl, has achieved clinical proof of concept in chronic kidney disease, a condition affecting over 26 million Americans. Bardoxlone is now in late stage clinical studies in diabetic patients with chronic kidney disease.

	- LEARN MORE